Anna Gilmore, Professor of Public Health and Co-Director of the Centre for 21st Century Public Health (C21PH) at the University of Bath, has urged governments across Europe to regulate the major industries and commercial actors that undermine climate and health protection efforts, following the release of a major report today. 

Prof Gilmore contributed expert analysis on how commercial actors shape human and planetary health outcomes to the latest report, published today, of the Pan-European Commission on Climate and Health (PECCH), an independent advisory group convened by the World Health Organisation (WHO). 

A new analysis in The Lancet Diabetes & Endocrinology challenges the belief that “yo‑yo dieting” is harmful. Reviewing human and animal studies, the authors find no convincing evidence that weight cycling causes lasting damage. While regaining weight reverses benefits, it does not worsen health beyond baseline. Overall, the findings suggest that attempting weight loss—even without long‑term success—is beneficial and should not be discouraged.

An experimental drug developed from research at the Medical University of South Carolina is showing early promise for some patients with advanced prostate cancer whose disease no longer responds to standard hormone therapies. In a Phase 2 clinical trial, researchers tested opaganib in combination with existing treatments and found that a subset of patients experienced encouraging signs that the therapy may be slowing the disease, including drops in blood markers linked to prostate cancer and periods of disease stabilization. Researchers are now analyzing blood samples from patients in the trial to identify biomarkers that could help predict who is most likely to benefit from the treatment. The findings could help advance a more personalized approach to prostate cancer care while opening the door to future therapies targeting the same biological pathway.